StreetInsider.com News Articles

Aprea Therapeutics shares Phase 1 data for cancer drug APR-1051

Mon, 01 Jun 2026 08:00:56 -0400

Aprea Therapeutics Inc. (NASDAQ: APRE) presented updated Phase 1 data for its WEE1 inhibitor APR-1051 at the American Society of Clinical Oncology annual meeting. The poster presentation showed early clinical activity in patients with advanced solid tumors.

The ACESOT-1051 study enrolled 28 patients with advanced solid tumors harboring specific cancer-associated gene alterations at doses ranging from 10 mg to 300 mg once daily. Two patients with endometrial cancers achieved partial responses, while six additional patients achieved stable disease across multiple tumor types including colorectal cancer and head and neck squamous cell carcinoma.

Treatment-related adverse events occurred in 54% of patients, with nausea

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Mon, 01 Jun 2026 08:00:00 -0400

Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types
Manageable tolerability confirmed across cohorts
Patient expansion into uterine serous carcinoma and platinum-resistant ovarian cancer underway; dose escalation and backfill expansion expected to complete Q2 2027

DOYLESTOWN, Pa., June 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, announces the presentation of a poster “Early results from the first-in-human phase 1 study

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Mon, 01 Jun 2026 08:00:00 -0400

Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types
Manageable tolerability confirmed across cohorts
Patient expansion into uterine serous carcinoma and platinum-resistant ovarian cancer underway; dose escalation and backfill expansion expected to complete Q2 2027

Form SCHEDULE 13G Aprea Therapeutics, Inc. Filed by: Vestal Point Capital, LP

Fri, 15 May 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260515/26507596.html

Form SCHEDULE 13G Aprea Therapeutics, Inc. Filed by: Vestal Point Capital, LP

Fri, 15 May 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260515/26507596.html

Form 424B7 Aprea Therapeutics, Inc.

Fri, 15 May 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260515/26506729.html

Form 424B7 Aprea Therapeutics, Inc.

Fri, 15 May 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260515/26506729.html

Aprea (APRE) PT Lowered to $6 at Wedbush

Wed, 13 May 2026 16:10:59 -0400

Wedbush analyst Robert Driscoll lowered the price target on Aprea (NASDAQ: APRE) to $6.00 (from $7.00) while maintaining a Outperform rating.

Aprea Therapeutics (APRE) Misses Q1 EPS by 22c

Wed, 13 May 2026 06:51:36 -0400

Aprea Therapeutics (NASDAQ: APRE) reported Q1 EPS of ($0.22).

For earnings history and earnings-related data on Aprea Therapeutics (APRE) click here.

Form 10-Q Aprea Therapeutics, Inc. For: Mar 31

Wed, 13 May 2026 06:46:00 -0400

si-local-file:///var/storage/secattach/20260513/26481307.html

Form 10-Q Aprea Therapeutics, Inc. For: Mar 31

Wed, 13 May 2026 06:46:00 -0400

si-local-file:///var/storage/secattach/20260513/26481307.html

Form 8-K Aprea Therapeutics, Inc. For: May 13

Wed, 13 May 2026 06:35:00 -0400

si-local-file:///var/storage/secattach/20260513/26481248.html

Form 8-K Aprea Therapeutics, Inc. For: May 13

Wed, 13 May 2026 06:35:00 -0400

si-local-file:///var/storage/secattach/20260513/26481248.html

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Wed, 13 May 2026 06:30:00 -0400

Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051
Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose escalation ACESOT-1051 trial of WEE1 inhibitor APR-1051
Additional clinical data from ACESOT-1051 to be provided at the ASCO 2026 Annual Meeting on May 30, 2026
$46.5 million in cash and cash equivalents as of March 31, 2026, with anticipated cash runway into Q1 2028